An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Trial Profile

An Open Label Phase 1b/2 Study of Orally Administered PLX 3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Pexidartinib (Primary) ; Temozolomide
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 07 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 19 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top